MedTrace Logo

Arthralgia During Anastrozole Therapy for Breast Cancer

NCT00323479 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2012-04-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.

Conditions

  • Early Breast Cancer

Interventions

DRUG

Anastrozole

1mg/Day oral

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca France Medical Director, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00323479 on ClinicalTrials.gov